Cancer Care Ontario guaiac fecal occult blood test (FOBT) laboratory standards: Evidentiary base and recommendations

Clinical Biochemistry

Volumn 41, Issue 16-17, 2008, Pages 1289-1305

  Rabeneck, Linda ^a   Zwaal, Caroline ^b   Goodman, Joel Hartley ^c   Mai, Verna ^d   Zamkanei, Mo ^e  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c DYNACARE LABORATORIES   (Canada)

^d Screening Programs   (Canada)

^e GRAND RIVER HOSPITAL   (Canada)

Author keywords

Cancer Screening; Colon cancer; Colorectal cancer; Fecal Occult Blood Test; FOBT; Laboratory Standards

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; CITRUS FRUIT EXTRACT; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; COLORECTAL CANCER; FECES ANALYSIS; GUAIAC FECAL OCCULT BLOOD TEST KIT; HUMAN; INTERNET; LABORATORY APPARATUS, EQUIPMENT AND SUPPLIES; PRIORITY JOURNAL; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ADULT; AGED; AGED, 80 AND OVER; CHEMISTRY, CLINICAL; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; GUAIAC; HUMANS; INTERNET; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; ONTARIO; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 55249106400     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.08.069     Document Type: Review

References (57)

1. National Cancer Institute of Canada. Canadian cancer statistics 2008 (2008), National Cancer Institute of Canada, Toronto (ON)
2. McLeod R, Canadian Task Force On Preventive Health Care (CTFPHC). Screening strategies for colorectal cancer: systematic review and recommendations. London (ON): Canadian Task Force; 2001 Feb [cited 2007 Mar 05]. CTFPHC Technical Report No.: 01-2. Available from: http://www.ctfphc.org/Full_Text/CTF_CRC_TR_Final.pdf.
3. Hardcastle J.D., Chamberlain J.O., Robinson M.H., Moss S.M., Amar S.S., Balfour T.W., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 9040 (1996) 1472-1477
4. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., and Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 9040 (1996) 1467-1471
5. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N. Engl. J. Med. 328 19 (1993) 1365-1371
6. Ontario Expert Panel on Colorectal Cancer. Colorectal cancer screening: final report of the Ontario Expert Panel (1999), Cancer Care Ontario, Toronto (ON)
7. National Committee on Colorectal Cancer Screening. Recommendations for population-based colorectal cancer screening (2002), Public Health Agency of Canada, Ottawa (Canada)
8. Cancer Care Ontario: Ontario FOBT Project Steering Committee. Ontario FOBT project: final report [monograph on the Internet] (2006 Mar), Cancer Care Ontario, Toronto (ON). http://cancercare.on.ca/documents/OntarioFOBTProject [cited 2007 Apr 05]. Available from: http://cancercare.on.ca/documents/OntarioFOBTProject-FinalReport.pdf.
9. Rabeneck L., Rumble R.B., Axler J., Smith A., Armstrong D., Vinden C., et al. Cancer Care Ontario colonoscopy standards: standards and evidentiary base. Can. J. Gastroenterol. 21 Suppl D (2007) 5D-24D
10. Hewitson P., Glasziou P., Watson E., Towler B., and Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am. J. Gastroenterol. 103 (2008) 1541-1549
11. Rabeneck L, Paszat LF, Hilsden RJ, Saskin R, Leddin D, Grunfeld E, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008; in press.
12. Beckman Coulter Inc. Hemoccult: routine screening test for fecal occult blood: product instructions (2000), Beckman Coulter, Inc., Fullerton (CA)
13. Beckman Coulter Inc. Hemoccult II SENSA: product instructions (2002), Beckman Coulter, Inc., Fullerton (CA)
14. Helena Laboratories. ColoScreen: a test for occult blood (2003), Helena Laboratories, Beaumont (TX)
15. Cenogenics Corporation. Cenogenics tri-slide, single slide and tape stool blood tests (2004) Morganville (NJ)
16. Immunostics Inc. Hema Screen (2004), Immunostics, Inc., Ocean (NJ)
17. Bennitt W, Burtonwood C, Halloran S. Four faecal occult blood test kits. [monograph on the Internet]. London (UK): NHS Purchasing and Supply Agency, Centre for Evidence-based Purchasing: 2006 Jan [cited 2007 Mar 02]. Report No.: 05110. Available from: http://www.pasa.nhs.uk/pasaweb/nhsprocurement/centreforevidencebasedpurc hasing/cepoutputs/laboratorymedicine.htm.
18. Pearson D, Bennitt W, Halloran S. Evaluation of eleven faecal occult blood test kits. London (UK): Medical Devices Agency (MDA): 2000 Mar [cited 2007 Apr 05]. MDA Evaluation Report No.: MDA/2000/05. Available from: http://www.pasa.doh.gov.uk/evaluation/docs/pathology/MDA_00_05.pdf.
19. Soares-Weiser K., Burch J., Duffy S., St John J., Smith S., Westwood M., et al. Diagnostic accuracy and cost-effectiveness of faecal occult blood tests (FOBT) used in screening for colorectal cancer: a systematic review [monograph on the Internet] (2007), York Publishing Services, York (UK). http://www.york.ac.uk/inst/crd/pdf/report36.pdf [cited 2007 Apr 05]. Available from: http://www.york.ac.uk/inst/crd/pdf/report36.pdf
20. Ahlquist D.A., Wieand H.S., Moertel C.G., McGill D.B., Loprinzi C.L., O'Connell M.J., et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 269 10 (1993) 1262-1267
21. Allison J.E., Tekawa I.S., Ransom L.J., and Adrain A.L. A comparison of fecal occult-blood tests for colorectal-cancer screening. N. Engl. J. Med. 334 3 (1996) 155-159
22. Bang K.M., Tillett S., Hoar S.K., Blair A., and McDougall V. Sensitivity of fecal hemoccult testing and flexible sigmoidoscopy for colorectal cancer screening. J. Occup. Med. 28 8 (1986) 709-713
23. Castiglione G., Sala P., Ciatto S., Grazzini G., Mazzotta A., Rossetti C., et al. Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions. Eur. J. Cancer Prev. 3 5 (1994) 399-405
24. Faivre J., Dancourt V., Lejeune C., Tazi M.A., Lamour J., Gerard D., et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126 7 (2004) 1674-1680
25. Guittet L., Bouvier V., Mariotte N., Vallee J.P., Arsene D., Boutreux S., et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56 2 (2007) 210-214
26. Jouve J.L., Remontet L., Dancourt V., Lejeune C., Benhamiche A.M., Faivre J., et al. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br. J. Cancer 84 11 (2001) 1477-1481
27. Kewenter J., Brevinge H., Engaras B., Haglind E., and Ahren C. Follow-up after screening for colorectal neoplasms with fecal occult blood testing in a controlled trial. Dis. Colon. Rectum 37 2 (1994) 115-119
28. Ko C.W., Dominitz J.A., and Nguyen T.D. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am. J. Med. 115 2 (2003) 111-114
29. Levin B., Hess K., and Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch. Intern. Med. 157 9 (1997) 970-976
30. Moss S.M., Hardcastle J.D., Coleman D.A., Robinson M.H., and Rodrigues V.C. Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test. Int. J. Epidemiol. 28 3 (1999) 386-390
31. Petrelli N., Michalek A.M., Freedman A., Baroni M., Mink I., and Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg. Oncol. 3 1 (1994) 27-36
32. Rennert G., Rennert H.S., Miron E., and Peterburg Y. Population colorectal cancer screening with fecal occult blood test. Cancer Epidemiol. Biomarkers Prev. 10 11 (2001) 1165-1168
33. Robinson M.H., Marks C.G., Farrands P.A., Thomas W.M., and Hardcastle J.D. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br. J. Surg. 81 3 (1994) 448-451
34. UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 329 7458 (2004) 133
35. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Turnbull B.A., and Ross M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 351 26 (2004) 2704-2714
36. Lieberman D.A., and Weiss D.G. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N. Engl. J. Med. 345 8 (2001) 555-560
37. Sung J.J., Chan F.K., Leung W.K., Wu J.C., Lau J.Y., Ching J., et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 124 3 (2003) 608-614
38. Greenwald B. A pilot study evaluating two alternate methods of stool collection for the fecal occult blood test. Medsurg. Nursing. 15 2 (2006) 89-94
39. Pignone M., Campbell M.K., Carr C., and Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff. Clin. Pract. 4 4 (2001) 150-156
40. Rozen P., Knaani J., and Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Dig. Dis. Sci. 44 4 (1999) 756-760
41. Sinatra M.A., St John D.J., and Young G.P. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Clin. Chem. 45 1 (1999) 123-126
42. Clarke P., Jack F., Carey F.A., and Steele R.J. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal. Dis. 8 5 (2006) 389-392
43. Kahi C.J., and Imperiale T.F. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am. J. Med. 117 11 (2004) 837-841
44. Pye G., Ballantyne K.C., Armitage N.C., and Hardcastle J.D. Influence of non-steroidal anti-inflammatory drugs on the outcome of faecal occult blood tests in screening for colorectal cancer. Br. Med. J. (Clin. Res. Ed.) 294 6586 (1987) 1510-1511
45. Jaffe R.M., Kasten B., Young D.S., and MacLowry J.D. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann. Intern. Med. 83 6 (1975) 824-826
46. Lifton L., and Kreiser J. False-positive stool occult blood tests caused by iron preparations. Gastroenterology 83 4 (1982) 860-863
47. Anderson G., Yuellig T., and Krone R. An investigation into the effects of oral iron supplementation an in vivo Hemoccult stool testing. Am. J. Gastroenterol. 85 5 (1990) 558-561
48. McDonnell W., Ryan J., Seeger D., and Elta G. Effect of iron on the guaiac reaction. Gastroenterology 96 1 (1989) 74-78
49. Greenberg P.D., Cello J.P., and Rockey D.C. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest. Endosc. 50 5 (1999) 618-622
50. Greenberg P.D., Cello J.P., and Rockey D.C. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am. J. Med. 100 6 (1996) 598-604
51. Norfleet R.G. 1300 mg of aspirin daily does not cause positive fecal hemoccult tests. J. Clin. Gastroenterol. 5 2 (1983) 123-125
52. Ransohoff D.F., and Lang C.A. Clinical guideline: Part II: Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann. Intern. Med. 126 10 (1997) 811-822
53. Young G., Sinatra M., and St. John J. Influence of delay in stool sampling on fecal occult blood test sensitivity. Clin. Chem. 42 7 (1996) 1107-1108
54. Selinger R.R., Norman S., and Dominitz J.A. Failure of health care professionals to interpret fecal occult blood tests accurately. Am. J. Med. 114 1 (2003) 64-67
55. Fleisher M., Winawer S.J., Zauber A.G., Smith C., and Schwartz M.K. National Polyp Study Work Group. Accuracy of fecal occult blood test interpretation. Ann. Intern. Med. 114 10 (1991) 875-876
56. Niv Y. Fecal occult blood test-the importance of proper evaluation. J. Clin. Gastroenterol. 12 4 (1990) 393-395
57. Collins J.F., Lieberman D.A., Durbin T.E., and Weiss D.G. Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann. Intern. Med. 142 2 (2005) 81-85